N4 Pharma PLC Nuvec® research update (3593F)
29 Oktober 2018 - 8:00AM
UK Regulatory
TIDMN4P
RNS Number : 3593F
N4 Pharma PLC
29 October 2018
29 October 2018
N4 Pharma Plc
("N4 Pharma" or the "Company")
Nuvec(R) research update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing a novel delivery system for vaccines and cancer
treatments, today announces an update on the latest key research
findings for the Company's Nuvec(R) delivery system.
As announced on 18 June 2018, the Company has been undertaking a
key research study to determine the level of immune response
Nuvec(R) can deliver when combined with a target antigen. This
study has been undertaken using both messenger RNA ("mRNA") and
plasmid DNA ("pDNA") encoded with the standard test antigen
Ovalbumin ("OVA"). The work has been performed both by N4 Pharma
and as part of the Company's grant collaboaration with MedImmune
UK, announced on 2 February 2018.
The results demonstrate that the Nuvec(R) particles themselves
have a clear adjuvant effect to help deliver a level of immune
response for both the mRNA and pDNA OVA antigens comparable to that
of existing delivery systems. The fact that Nuvec(R) provides such
an adjuvant response directly means an additional adjuvant would
not be required when formulating a vaccine using Nuvec(R) as the
delivery system. This would simplify and reduce the production cost
of the final vaccine and mean less antigen would be required.
Furthermore, the level of immune response is generated using a dose
of Nuvec(R) particles that is within acceptable levels showing no
adverse toxicity.
The data received to date indicates that Nuvec(R) will be
suitable for use with multiple antigens. Following this, the
Company has now shown successful loading and delivery of mRNA as
well as pDNA and now have both in vitro and in vivo data to show
that Nuvec(R) not only delivers the mRNA and pDNA intracellularly,
it does so to a sufficient level to generate a required immune
response.
Additional studies to optimise the loading properties of
Nuvec(R) and to characterise the immune response are in progress.
The Company will provide further updates following the conclusion
of these studies.
Nigel Theobald, CEO of N4 Pharma commented:
"These results are another positive step forward for our
Nuvec(R) delivery platform. The data validates the potential of
Nuvec(R) to act as an alternative delivery system for the
development of vaccines and cancer treatments but without the
associated unwanted systemic side effects and with no signs of
liver toxicity often seen using lipid nanoparticle systems.
"Our next research study will focus on demonstrating the ability
of Nuvec(R) to deliver an effective level of immunity using OVA,
results of which will be available in first half of 2019.
"We are pleased with the Nuvec(R) results received to date and
will continue to focus on the many opportunities that we believe
will exist for Nuvec(R) to be used to develop a range of different
vaccines and cancer treatments. We are building a compelling data
package to aide our commercial collaboaration discussions which we
continue to progress."
Enquiries:
N4 Pharma Plc
Nigel Theobald, CEO Via Alma PR
Allenby Capital Limited Tel: +44(0)203 328 5656
James Reeve/Virginia Bull/Asha
Chotai
Alma PR
Josh Royston Tel: +44(0)778 090 1979
Robyn Fisher Tel: +44(0)754 070 6191
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for vaccines and cancer treatments using its
unique silica nanoparticle delivery system called Nuvec(R)
Nuvec(R) has shown to be capable of loading and delivering mRNA
and pDNA into cells to the required level needed to generate an
immune response. Further work will be undertaken for the direct
loading and delivery of peptides and proteins using Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for vaccines and cancer treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immune response. As
these products progress through pre clinical and clinical programs
N4 will receive up front and milestone payments and ultimately
royalty payments once products reach the market.
Glossary:
Adjuvant: An immunological agent that is used in vaccines to
help boost the immune response to produce more antibodies for
longer lasting immunity.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RESXQLFLVBFBFBF
(END) Dow Jones Newswires
October 29, 2018 03:00 ET (07:00 GMT)
N4 Pharma (LSE:N4P)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
N4 Pharma (LSE:N4P)
Historical Stock Chart
Von Jul 2023 bis Jul 2024